Abstract
Objectives: To assess the pharmacological costs of pembrolizumab in association with chemotherapy as first-line treatment in non small-cell lung cancer (NSCLC). Methods: Pivotal phase III randomized controlled trials (RCTs) were considered. Differences in progression free survival (PFS) between the different arms were calculated and compared with the pharmacological costs needed to get one month of PFS (incremental cost-effectiveness ratio, ICER). Results: One thousand one hundred and seventy five patients were included.Differences in costs between the 2 arms with the use of pembrolizumab were 37 009 € for squamous NSCLC and 45 234 € for nonsquamous NSCLC, with a cost of 23 131 € and 11 598 € per month of PFS-gain in the overall population for squamous and nonsquamous NSCLC, respectively and with a progressively lower cost per month of PFS-gain in the transition from PD-L1< 1% (37 009 €) to PD-L1 of 1 to 49% (18 505 €) to PD-L1? 50% (9739 €) in squamous and NSCLC. Conclusion: At the actual prize, pembrolizumab in combination with chemotherapy is not cost-effective in first-line for both squamous and nonsquamous NSCLC. A reduction in pharmacy cost is mandatory. Keywords: Cost of drugs, NSCLC, pembrolizumab
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
